Clinical Trial Update: Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing prasugrel 5 mg with high-dose clopidogrel in clopidogrel-resistant patients after PCI; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: University of Patras | Conditions: Platelet Reactivity | Phase 4 | Status: COMPLETED